Product Information
HYDROCHLOROTHIAZIDE 12.5 MG TB is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.0340 per EA under NDC 00172344460. Its NADAC has been published 48 times since Nov 5, 2025.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12.5 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00172344460
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA083177FDA Approved
Before 1982
TE Code
AB
On Market Since
6/3/2025
Pharmacological Classes
Price Statistics
The NADAC for HYDROCHLOROTHIAZIDE 12.5 MG TB has been published 48 times since Nov 5, 2025, and over the history we have for it it has declined 17.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0340 per EA |
|---|---|
| All-time high | $0.0412 (Apr 15, 2026) |
| All-time low | $0.0340 (Sep 23, 2026) |
| 52-week high | $0.0412 |
| 52-week low | $0.0340 |
| Median price | $0.0404 |
| Average price | $0.0399 |
| Largest weekly change | -8.9% (Sep 23, 2026) |
| Weeks tracked | 48 |
| Tracking since | Nov 5, 2025 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Thiazide Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HYDROCHLOROTHIAZIDE 12.5 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for HYDROCHLOROTHIAZIDE 12.5 MG TB, manufactured by Teva Pharmaceuticals USA Inc., is $0.0340 per EA (NDC 00172344460), effective Sep 30, 2026.
How has the price of HYDROCHLOROTHIAZIDE 12.5 MG TB changed over time?
Over the history we have for it, the NADAC for HYDROCHLOROTHIAZIDE 12.5 MG TB has declined 17.2%. It has been tracked across 48 weekly CMS publications since Nov 5, 2025.
What are the highest and lowest recorded NADAC prices for HYDROCHLOROTHIAZIDE 12.5 MG TB?
Since Nov 5, 2025, the NADAC for HYDROCHLOROTHIAZIDE 12.5 MG TB has ranged from a low of $0.0340 (Sep 23, 2026) to a high of $0.0412 (Apr 15, 2026), with a median of $0.0404 per EA.
Are there cheaper alternatives to HYDROCHLOROTHIAZIDE 12.5 MG TB?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as HYDROCHLOROTHIAZIDE 12.5 MG TB in a comparable dosage form, but none are currently priced below it.
Who manufactures HYDROCHLOROTHIAZIDE 12.5 MG TB?
HYDROCHLOROTHIAZIDE 12.5 MG TB (NDC 00172344460) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.